MITSUBISHI CHEMICAL GROUP
MITSUBISHI CHEMICAL GROUP

Health Care

From KAITEKI Report 2023 issued in September 2023

Strengthening the pipeline and maximizing product value

To achieve our fiscal 2025 targets, we are focusing on (1) maximizing the value of priority products in Japan and the United States and (2) strengthening partnering and establishing new sales and development alliances. We restructured our business in fiscal 2022, including withdrawal from the business operated by Medicago Inc. that was developing a vaccine against COVID-19. We will now focus R&D spending on indications in the core areas of central nervous system, immuno-inflammation, and oncology, with the goal of strengthening our pipeline and maximizing product value.

Strategic focus

  • Advance precision medicine through upgraded R&D processes
  • Focus innovation development on rare diseases and continue to invest in a new pipeline
  • Leverage partnerships for development and sales
FY2021 results EBITDA 8.4 Billion of yen EBITDA margin 2％ Core operating margin（2％） ROIC （1％） FY2025 target EBITDA 55.0 Billion of yen EBITDA margin 15% Core operating margin 10% ROIC 3%
Change in EBITDA
FY2021 results 8.4 Billion of yen FY2025 target 55.0 Billion of yen Growth Business restructuring Strategic cost transformation NHI drug price revisions

SWOT analysis

SStrengths
  • New drug creation capabilities in the pharmaceuticals business
  • Strong presence in priority drug markets including central nervous system, immuno-inflammation, and diabetes and kidney
WWeaknesses
  • Delayed expansion into global markets
OOpportunities
  • Demand for provision of diverse healthcare solutions
  • Increasingly diverse drug discovery activities due to technological advances
  • Unmet medical needs
TThreats
  • Declining probability of success with drug discovery
  • Increasing R&D expenditures
  • Government measures to control healthcare expenditures, generic drugs entering the market

New treatment option for ALS patients

The oral suspension formulation of edaravone was approved as a treatment for amyotrophic lateral sclerosis (ALS) in the United States in May 2022, in Canada in November, in Japan in December, and in Switzerland in May 2023.
This oral suspension formulation of edaravone contains the same active ingredient as the intravenous infusion formulation RADICUT (U.S. product name: RADICAVA). We undertook its development with the aim of reducing burdens on ALS patients such as injection pain and outpatient visits. Previously, intravenous infusion was the only available route of administration, but now there is a new treatment option.

  • Launched
  • Global (FY of U.S. launch)
  • Japan, China
Area Focus Targeted indications Key markets MCG Group’s key growth products Launch plans for main pipeline programs
FY2022 FY2023 FY2024 From FY2025
Central nervous system Development, sales ALS,
Tardive dyskinesia		 U.S., Japan RADICAVA DYSVAL MT-1186 ALS (oral suspension) (U.S., Canada) MT-5199 Tardive dyskinesia (Japan) MT-1186 ALS (oral suspension) (Japan)*2 ND0612 Parkinson’s disease (global) MT-0551 Myasthenia gravis (Japan)
Immuno-inflammation Development, sales Inflammatory bowel disease,
Erythropoietic protoporphyria		 U.S., Japan STELARA
MT-7117		       MT-0551
IgG4-related disease (Japan) MT-7117 Erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP) (global)
Diabetes and kidney Sales Type 2 diabetes,
Chronic kidney disease (CKD) associated with type 2 diabetes		 Japan MOUNJARO CANAGLU TA-7284 CKD associated with type 2 diabetes*1 (Japan) MP-513 Type 2 diabetes (China)   TA-7284 OD tablets Type 2 diabetes, CKD associated with type 2 diabetes*1 (Japan)  
Oncology Development Rare cancers U.S., Japan MT-2111       MT-2111 Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) (Japan)
  • *1CKD associated with type 2 diabetes, but excludes patients with end-stage renal failure or undergoing dialysis
  • *2Approved in Switzerland

Back to top